Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Operating Leases (2020 - 2023)

Historic Operating Leases for Insight Molecular Diagnostics (IMDX) over the last 4 years, with Q1 2023 value amounting to $2.6 million.

  • Insight Molecular Diagnostics' Operating Leases fell 2333.13% to $2.6 million in Q1 2023 from the same period last year, while for Mar 2023 it was $2.6 million, marking a year-over-year decrease of 2333.13%. This contributed to the annual value of $2.7 million for FY2022, which is 2301.83% down from last year.
  • Per Insight Molecular Diagnostics' latest filing, its Operating Leases stood at $2.6 million for Q1 2023, which was down 2333.13% from $2.7 million recorded in Q4 2022.
  • Insight Molecular Diagnostics' Operating Leases' 5-year high stood at $4.3 million during Q4 2020, with a 5-year trough of $2.6 million in Q1 2023.
  • Its 4-year average for Operating Leases is $3.4 million, with a median of $3.5 million in 2021.
  • Per our database at Business Quant, Insight Molecular Diagnostics' Operating Leases plummeted by 1383.42% in 2022 and then tumbled by 2333.13% in 2023.
  • Quarter analysis of 4 years shows Insight Molecular Diagnostics' Operating Leases stood at $4.3 million in 2020, then fell by 17.79% to $3.5 million in 2021, then dropped by 23.02% to $2.7 million in 2022, then decreased by 6.56% to $2.6 million in 2023.
  • Its last three reported values are $2.6 million in Q1 2023, $2.7 million for Q4 2022, and $2.9 million during Q3 2022.